35 results
8-K
OCUL
Ocular Therapeutix Inc
3 Jun 24
Cost Associated with Exit or Disposal Activities
9:15am
% of the Company’s workforce, as part of an initiative to prioritize Company resources on the clinical development of AXPAXLI™ (axitinib intravitreal implant
424B5
8iztgd8lwhxrq
16 Dec 20
Prospectus supplement for primary offering
4:04pm
424B5
7gtrs e1g
14 Dec 20
Prospectus supplement for primary offering
5:21pm
424B5
1f8paltn6fq1r3 sc0x
14 Oct 20
Prospectus supplement for primary offering
4:17pm
424B5
1zl2mx q3d
13 Oct 20
Prospectus supplement for primary offering
5:24pm
424B5
a2c3v
20 May 20
Prospectus supplement for primary offering
4:27pm
424B5
hvg 7edlhbxp
19 May 20
Prospectus supplement for primary offering
4:54pm